Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214832 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL707452 | 0.85 | HSP90AA1 (0.44) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| Hydrochloric Acid SCHEMBL5121 | 0.85 | — | — | |
| T-Butylacetic Acid SCHEMBL28948304 | 0.81 | HDAC3 (0.38) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL874457 | 0.75 | KDM4E (0.48) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL1483374 | 0.73 | ADORA3 (0.50) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| Hydrochloric Acid SCHEMBL1373071 | 0.73 | KDM4E (0.47) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL15572500 | 0.73 | KDM4E (0.47) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL15571571 | 0.73 | KDM4E (0.47) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL15572404 | 0.73 | IDO1 (0.48) | KDM4ENAPRTHCAR2ADORA3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591223-B | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-3512851-B1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| CN-114591223-A | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-109715630-B | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| EP-3512851-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | Entasis Therapeutics Limited (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| WO-2018053215-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, MRPL21 | KDM4E 2131/4885NAPRT 1328/4885HCAR2 4094/4885 |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | LCT, MGAM, MRPL21 | KDM4E 2131/4885NAPRT 1328/4885HCAR2 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.